STOCK TITAN

Bolt Biotherapeutics (BOLT) Financials

BOLT NASDAQ
FY2025 annual
Revenue $7.7M +0.1% YoY
Net Income -$33.4M n/m YoY
EPS (Diluted) -$17.85 n/m YoY
Free Cash Flow -$39.9M n/m YoY
Market Cap $13.2M as of Nov 19, 2026
Price / Sales 5.2x on $2.5M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.5x on $8.6M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BOLT SEC filings page.

Bolt Biotherapeutics, Inc. (BOLT) reported $7.7M in revenue for fiscal year 2025, up 0.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BOLT FY2025

FY2025 shows a development-stage business cutting research spending faster than revenue changes, narrowing losses without reaching cash breakeven.

Revenue was essentially flat in FY2025, changing just 0.1%, while R&D fell 50.4%; the improvement therefore reflects a smaller development program more than sales growth. Operating loss narrowed to $36.1M, but operating cash flow was -$39.9M, showing that lower spending has not yet translated into cash breakeven.

R&D still equaled 370.8% of revenue, while capital expenditures were only 0.9% of revenue in FY2025; the cost base is research-led rather than asset-heavy. That combination means reported spending is concentrated in the development effort, not physical infrastructure.

Liabilities represented 53.3% of assets in FY2025 versus 29.4% in FY2023, indicating that losses have consumed balance-sheet cushion. The current ratio fell from 5.2x in FY2023 to 3.6x in FY2025, although short-term assets still exceeded current liabilities.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 58 / 100
Financial Health Score (5 of 6 dimensions) 58/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bolt Biotherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
31

Bolt Biotherapeutics, Inc. held $31.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $39.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Bolt Biotherapeutics, Inc. scores 31/100 among other emerging companies.

Dilution
n/a

Not available for Bolt Biotherapeutics, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

R&D Intensity
85

Bolt Biotherapeutics, Inc. spent $28.5M on research and development in fiscal year 2025, which was 65.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Bolt Biotherapeutics, Inc. scores 85/100 among other emerging companies.

Revenue Progress
42

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Bolt Biotherapeutics, Inc. scores 42/100 on it among other emerging companies.

Burn Trend
71

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Bolt Biotherapeutics, Inc. scores 71/100 on it among other emerging companies.

Balance Sheet
62

Bolt Biotherapeutics, Inc.'s cash, cash equivalents and investments came to $31.8M at the end of fiscal year 2025, against $30.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Bolt Biotherapeutics, Inc. scores 62/100 among other emerging companies.

Altman Z-Score Distress
-12.61

Bolt Biotherapeutics, Inc. scores -12.61, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $460.8M against total assets of $56.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/7

Bolt Biotherapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Bolt Biotherapeutics, Inc. reported a net loss of $33.4M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoY-100.0%
QoQ-100.0%

Bolt Biotherapeutics, Inc. generated $0 in revenue in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

EBITDA
-$4.7M
YoYn/m
QoQn/m

Bolt Biotherapeutics, Inc.'s EBITDA was -$4.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$4.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Bolt Biotherapeutics, Inc. reported a net loss of $4.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$2.25
YoYn/m
QoQn/m
5Y CAGRn/m

Bolt Biotherapeutics, Inc. earned -$2.25 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$3.1M
YoYn/m

Bolt Biotherapeutics, Inc. recorded an outflow of $3.1M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Debt
$13.8M
YoY-22.4%
QoQ+7.2%
5Y CAGR-10.2%

Bolt Biotherapeutics, Inc. held $13.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
3M
YoY+35.8%
QoQ+35.4%
5Y CAGR+6.9%

Bolt Biotherapeutics, Inc. had 3M shares outstanding in Q3 2026. This represents an increase of 35.8% from the same quarter a year earlier. Against the prior quarter it is up 35.4%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-51.6%
YoY-29.4pp
QoQ+8.1pp
5Y change-43.1pp

Bolt Biotherapeutics, Inc.'s quarterly ROE was -51.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 29.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$2.2M
YoY-66.2%
QoQ-53.2%
5Y CAGR-35.2%

Bolt Biotherapeutics, Inc. invested $2.2M in research and development in Q3 2026. This represents a decrease of 66.2% from the same quarter a year earlier. Against the prior quarter it is down 53.2%.

Capital Expenditures
$0
YoY-100.0%

Bolt Biotherapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

BOLT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BOLT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0-100.0%$5K-99.7%$26K-97.9%$2.5Mn/m$2.2M+90.1%$1.8M+41.5%$1.2M-76.8%$0-100.0%
R&D Expenses$2.2M-66.2%$4.7M-37.0%$5.3M-44.8%$5.0M-57.4%$6.5M-52.6%$7.5M-51.4%$9.5M-42.5%$11.7M-28.2%
SG&A Expenses$2.5M-24.5%$2.4M-31.1%$2.8M-26.8%$3.1M-21.0%$3.3M-12.2%$3.5M-27.9%$3.8M-34.5%$3.9M-28.7%
Operating Income-$4.7Mn/m-$7.9Mn/m-$8.0Mn/m-$7.1Mn/m-$7.7Mn/m-$9.2Mn/m-$12.1Mn/m-$16.9Mn/m
EBITDA-$4.7Mn/m-$7.8Mn/m-$7.8Mn/m-$6.8Mn/m-$7.4Mn/m-$8.9Mn/m-$11.7Mn/m-$16.5Mn/m
Net Income-$4.4Mn/m-$7.5Mn/m-$7.7Mn/m-$6.6Mn/m-$7.1Mn/m-$8.6Mn/m-$11.0Mn/m-$15.9Mn/m
EPS (Basic)-$2.25n/m-$3.88n/m-$3.99n/m-$3.91n/m-$3.72n/m-$4.46n/m-$5.76n/m-$8.33n/m
EPS (Diluted)-$2.25n/m-$3.88n/m-$3.99n/m-$3.91n/m-$3.72n/m-$4.46n/m-$5.76n/m-$8.33n/m
Diluted Shares (Avg)2M+2.4%2M+0.3%2M+0.2%N/A2M+0.4%2M+0.6%2M+0.7%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

BOLT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BOLT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$35.6M-45.3%$40.2M-46.8%$48.0M-44.1%$56.7M-43.0%$65.1M-40.5%$75.5M-39.2%$85.9M-39.9%$99.6M-37.6%
Current Assets$17.1M-52.0%$20.6M-46.4%$25.8M-39.4%$30.3M-40.4%$35.6M-37.7%$38.3M-50.0%$42.5M-55.3%$50.8M-51.9%
Cash & Equivalents$13.8M-22.4%$12.9M+33.9%$11.6M+38.4%$11.7M+62.4%$17.8M+89.5%$9.6M+54.8%$8.4M+96.9%$7.2M-33.3%
Short-Term Investments$1.0M-92.8%$4.7M-81.2%$11.3M-62.9%$15.8M-60.6%$14.2M-68.1%$25.2M-62.7%$30.4M-65.0%$40.1M-56.1%
Long-Term Investments$247K-96.4%$509K-96.3%$1.0M-94.7%$4.3M-81.0%$6.9M-77.4%$13.7M-42.4%$19.1M-10.9%$22.9M-13.4%
Total Liabilities$27.0M-18.0%$27.7M-24.4%$28.6M-26.7%$30.2M-28.7%$33.0M-11.7%$36.7M-4.3%$39.1M+0.8%$42.4M-9.8%
Current Liabilities$8.3M-16.6%$7.9M-36.1%$7.8M-42.7%$8.4M-46.8%$10.0M-44.9%$12.3M-31.2%$13.6M-18.9%$15.9M-22.5%
Non-Current Liabilities$18.7M-18.6%$19.8M-18.5%$20.9M-18.2%$21.8M-17.9%$23.0M+19.6%$24.3M+19.3%$25.5M+15.8%$26.6M0.0%
Total Equity$8.6M-73.3%$12.5M-67.9%$19.4M-58.6%$26.5M-53.7%$32.1M-55.4%$38.8M-54.8%$46.8M-55.1%$57.2M-49.3%
Retained Earnings-$480.3Mn/m-$475.9Mn/m-$468.4Mn/m-$460.8Mn/m-$454.1Mn/m-$447.0Mn/m-$438.4Mn/m-$427.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BOLT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BOLT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$3.1Mn/m-$6.5Mn/m-$8.0Mn/m-$7.2Mn/m-$9.7Mn/m-$9.6Mn/m-$13.4Mn/m-$14.4Mn/m
Depreciation & Amortization$66K-77.2%$171K-50.7%$203K-49.1%$255K-40.1%$290K-34.1%$347K-24.1%$399K-12.9%$426K-8.8%
Stock-Based Compensation$506K+24.3%$552K-11.7%$545K-23.1%N/A$407K-62.9%$625K-77.9%$709K-69.2%N/A
Capital Expenditures$0-100.0%N/AN/A$0n/m$72K+75.6%N/AN/A$0-100.0%
Free Cash Flow-$3.1Mn/mN/AN/A-$7.2Mn/m-$9.8Mn/mN/AN/A-$14.4Mn/m
Investing Cash Flow$4.0M-77.6%$7.8M-28.0%$7.9M-45.6%$1.1M-91.2%$17.9M+4.4%$10.8M-40.0%$14.6M+42.6%$12.2M-22.6%
Financing Cash Flow$0n/m$19K+35.7%$6Kn/m$5K-82.8%$0n/m$14K-82.3%$0n/m$29K-72.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BOLT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BOLT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/A-158980.0%-30869.2%-283.4%-355.1%-510.5%-991.4%N/A
Net MarginN/A-149160.0%-29496.2%-265.2%-329.4%-474.6%-903.4%N/A
Return on Equity-51.6%-29.4pp-59.8%-37.7pp-39.5%-16.0pp-25.0%+2.8pp-22.3%-1.2pp-22.0%+2.6pp-23.6%-13.2pp-27.9%-12.0pp
Return on Assets-12.4%-1.4pp-18.6%-7.2pp-16.0%-3.1pp-11.7%+4.3pp-11.0%+2.9pp-11.3%+5.7pp-12.9%-5.3pp-16.0%-4.8pp
Current Ratio2.05-1.5x2.61-0.5x3.32+0.2x3.59+0.4x3.57+0.4x3.11-1.2x3.13-2.5x3.20-2.0x
Liabilities-to-Equity3.16+2.1x2.22+1.3x1.48+0.6x1.14+0.4x1.03+0.5x0.94+0.5x0.83+0.5x0.74+0.3x
Asset Turnover0.000.0x0.000.0x0.000.0x0.040.0x0.030.0x0.020.0x0.010.0x0.000.0x
FCF MarginN/AN/AN/A-286.2%-452.0%N/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Bolt Biotherapeutics, Inc. BOLT FY2025 $7.7M -$33.4M N/A $13.2M 58/100
Akari Therapeutics plc AKTX FY2025 N/A -$17.3M N/A $15.6M —
Context Therapeutics Inc. CNTX FY2025 N/A -$36.1M N/A $15.5M —
Allarity Therapeutics, Inc. ALLR FY2025 $320K -$11.2M N/A $13.8M —
Marker Therapeutics, Inc. MRKR FY2025 $3.5M -$12.2M N/A $22.0M 60/100
Seres Therapeutics, Inc. MCRB FY2025 $789K $5.7M N/A $13.6M —

Frequently Asked Questions

Bolt Biotherapeutics, Inc. (BOLT) reported $7.7M in total revenue for fiscal year 2025. This represents a 0.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Bolt Biotherapeutics, Inc. (BOLT) revenue grew by 0.1% year-over-year, from $7.7M to $7.7M in fiscal year 2025.

No, Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $33.4M in fiscal year 2025.

Bolt Biotherapeutics, Inc. (BOLT) reported diluted earnings per share of -$17.85 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bolt Biotherapeutics, Inc. (BOLT) had EBITDA of -$34.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Bolt Biotherapeutics, Inc. (BOLT) has a return on equity of -125.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Bolt Biotherapeutics, Inc. (BOLT) recorded an outflow of $39.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Bolt Biotherapeutics, Inc. (BOLT) recorded an outflow of $39.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Bolt Biotherapeutics, Inc. (BOLT) had $56.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Bolt Biotherapeutics, Inc. (BOLT) invested $72K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Bolt Biotherapeutics, Inc. (BOLT) invested $28.5M in research and development during fiscal year 2025.

Bolt Biotherapeutics, Inc. (BOLT) had 2M shares outstanding as of fiscal year 2025.

Bolt Biotherapeutics, Inc. (BOLT) had a current ratio of 3.59 as of fiscal year 2025, which is generally considered healthy.

Bolt Biotherapeutics, Inc. (BOLT) had a liabilities-to-equity ratio of 1.14 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Bolt Biotherapeutics, Inc. (BOLT) had a return on assets of -58.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Bolt Biotherapeutics, Inc. (BOLT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $13.2M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Bolt Biotherapeutics, Inc. (BOLT) trades at 5.2x sales, its market capitalization divided by $2.5M revenue, trailing 12 months to September 30, 2026. The market capitalization is $13.2M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Bolt Biotherapeutics, Inc. (BOLT) held $31.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Bolt Biotherapeutics, Inc. (BOLT) has an Altman Z-Score of -12.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Bolt Biotherapeutics, Inc. (BOLT) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $33.4M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Bolt Biotherapeutics, Inc. (BOLT) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Bolt Biotherapeutics, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top